


**Product Name** : GSK3494245  
**Cat. No.** : PC-36167  
**CAS No.** : 2080410-41-7  
**Molecular Formula** : C<sub>21</sub>H<sub>23</sub>FN<sub>6</sub>O<sub>2</sub>  
**Molecular Weight** : 410.453  
**Target** : Parasite  
**Solubility** : 10 mM in DMSO



## Biological Activity

GSK3494245 (DDD01305143, GSK-3494245) is a preclinical candidate for **Visceral leishmaniasis** (VL) by inhibition of the chymotrypsin-like activity catalyzed by the  $\beta$ 5 subunit of the **L. donovani proteasome** with IC<sub>50</sub> of 0.16  $\mu$ M.

GSK3494245 demonstrates promising pharmacokinetic properties and impressive in vivo efficacy in mouse model of infection comparable with those of the current oral antileishmanial miltefosine.

GSK3494245 shows potency against nonpathogenic Leishmania spp. Leishmania tarentolae (EC<sub>50</sub>=40 nM), which is comparable with that achieved against L. donovani promastigotes (EC<sub>50</sub>=14 nM); orally active.

## References

Wyllie S, et al. *Proc Natl Acad Sci U S A*. 2019 Apr 8. pii: 201820175.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com